Vorapaxar in the Secondary Prevention of Atherothrombotic Events | Zendy

David A. Morrow | Zendy; Eugene Braunwald | Zendy; Marc P. Bonaca | Zendy; Sebastián F. Ameriso | Zendy; Anthony J. Dalby | Zendy; Mary Polly Fish | Zendy; Keith A.A. Fox | Zendy; Leslie Lipka | Zendy; Xuan Liu | Zendy; José Carlos Nicolau | Zendy; A.J. Oude Ophuis | Zendy; Ernesto Paolasso | Zendy; Benjamin M. Scirica | Zendy; Jindřich Špinar | Zendy; Pierre Théroux | Zendy; Stephen D. Wiviott | Zendy; John Strony | Zendy; Sabina A. Murphy | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Vorapaxar in the Secondary Prevention of Atherothrombotic Events

Author(s) -

David A. Morrow,

Eugene Braunwald,

Marc P. Bonaca,

Sebastián F. Ameriso,

Anthony J. Dalby,

Mary Polly Fish,

Keith A.A. Fox,

Leslie Lipka,

Xuan Liu,

José Carlos Nicolau,

A.J. Oude Ophuis,

Ernesto Paolasso,

Benjamin M. Scirica,

Jindřich Špinar,

Pierre Théroux,

Stephen D. Wiviott,

John Strony,

Sabina A. Murphy

Publication year - 2012

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1200933

Subject(s) - medicine , hazard ratio , myocardial infarction , stroke (engine) , cardiology , placebo , confidence interval , pathology , mechanical engineering , alternative medicine , engineering

Thrombin potently activates platelets through the protease-activated receptor PAR-1. Vorapaxar is a novel antiplatelet agent that selectively inhibits the cellular actions of thrombin through antagonism of PAR-1.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research